12/22 Glaxo Shingles Vaccine: Stunning Efficacy Could Challenge Merck
New GSK shingles vaccine may challenge Merck after strong test data
reduced the risk of shingles by 97.2 percent in adults aged 50 years and older compared to placebo
result looks compelling compared to Zostavax, which has showed 69.8 percent efficacy in patients aged 50 to 59 years, and lower efficacy in older people
12/22 Viekira Pak: AbbVie Answer To Solvaldi, Harvoni Approved By FDA
- 12 week Viekira 12% less than 12 week Harvoni
FDA approves AbbVie all-oral hepatitis C treatment
AbbVie regimen consists of four different anti-viral drugs to be taken as three pills in the morning and one in the evening.
FDA Approves AbbVie's VIEKIRA PAK (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C Virus
VIEKIRA PAK consists of the fixed-dose combination of ombitasvir 25mg (an NS5A inhibitor), paritaprevir 150mg (an NS3/4A protease inhibitor), and ritonavir 100mg (an approved HIV-1 protease inhibitor), dosed once daily with a meal, and dasabuvir 250mg (a non-nucleoside NS5B palm polymerase inhibitor), dosed twice daily with a meal
[AbbVie Press Release]
AbbVie Prices Hepatitis C Drug 12% Below Gilead Rival
Viekira Pak could generate $2.9 billion in sales next year
revenue will help North Chicago, Illinois-based AbbVie expand its sources of revenue beyond best-seller Humira, the rheumatoid arthritis treatment that is projected by analysts to bring in $12.6 billion this year
12/22 Viekira Pak Versus Harvoni, Solvaldi: Tale Of The Tape
Abbvie's Hep C Regimen Approved, Marketing Battle With Gilead Up Next
patients treated with Viekira Pak will swallow three pills in the morning and one pill at night at a price of $83,000 for a 12-week course of treatment. Gliead's Harvoni costs $94,500 [for 12 weeks although some patients only take it for 8 weeks at a cost of $63K ]
12/22 Diabetes Linked To Cancer Again
A New Study on Diabetes Reveals Potentially Frightening News
patients with either type 1 or 2 diabetes have a higher incidence rate of cancer, and a higher death rate from cancer, than non-diabetics.
29.1 million people in the U.S. now have diabetes, of which more than one in four is unaware they have the chronic disease. This is up from 26 million in the CDC's last update. Further, the number of people with prediabetes has ballooned to 86 million from 79 million.
12/22 Express Scripts Eagerly Waits AZN, Lilly Patent Cliff
Patent Cliff Means Pharmaceutical Companies Will Lose $65 Billion by 2019, says GlobalData
hardest will include Otsuka, Eli Lilly, and AstraZeneca (AZ), with a significant proportion of losses coming in the Central Nervous System (CNS) treatment sector.
"AZN's CNS segment has been bleeding sales as a result of the company losing its patent on Seroquel (quetiapine fumarate)
Drug Giants Face $65 Billion in Lost Sales as Insurers Attack Patents
"In this environment, more than ever, we anticipate that payers will rely on Express Scripts' formulary and step management programs to maximize the savings potential of new generics
12/22 FDA approves Cubists' drug for antibiotic-resistant bacteria
- Novel antipseudomonal cephalosporin with an established beta-lactamase inhibitor.
FDA approves Cubists' drug for antibiotic-resistant bacteria
to treat complicated urinary tract and intra-abdominal infections won U.S. approval on Friday, highlighting the regulator's interest in tackling the growing threat of the so-called superbugs
faces competition from several other companies, including AstraZeneca Plc and Actavis Plc. The companies' rival drug is being reviewed by the FDA, which is expected to reach a decision in the first quarter of 2015.
Cubist Announces Approval of ZERBAXA (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections
first new antibiotic approved in the U.S. under the Generating Antibiotic Incentives Now (GAIN) Act to treat Gram-negative bacteria.
intravenous (I.V.) formulation at a 1.5 g q8h dose for the treatment of adults with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections
[Cubist Press Release]
12/22 Nobody Wants Those Garage Sale Drugs
Record Pharma-Deal Year Not Enough to Sell Mature Drugs
some of the largest pharmaceutical companies tried to sell their portfolios of older drugs -- and failed
"Private-equity firms and trade buyers are still very interested
Glaxo said it ended the sale of its North American and European established products, with annual sales of about 1 billion pounds ($1.6 billion), because the offers weren't high enough.